+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Respiratory Syncytial Virus Vaccine for the Elderly Market - Global Forecast 2025-2030- Product Image
Respiratory Syncytial Virus Vaccine for the Elderly Market - Global Forecast 2025-2030- Product Image
Sale

Respiratory Syncytial Virus Vaccine for the Elderly Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6081818
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Demand for elderly respiratory syncytial virus (RSV) vaccination is growing amid shifts in global immunization practices and technology. Biopharmaceutical companies, payers, and healthcare providers must navigate evolving clinical, logistical, and regulatory complexities to meet the needs of aging populations. Decision-makers require strategic market intelligence to inform investment, procurement, and stakeholder engagement in this dynamic landscape.

Market Snapshot: Elderly Respiratory Syncytial Virus Vaccination Landscape

The global elderly RSV vaccine market is shaped by rising incidence rates among adults aged 65 and older, prompting a surge in vaccine research, development, and deployment. New vaccines featuring recombinant, subunit, and mRNA technologies are transforming standards of care, while changing reimbursement and policy frameworks influence access and distribution. The introduction of new tariff regulations and enhanced cold-chain solutions further impacts supply chain and cost structures, particularly in regions reliant on imported vaccine components and specialized logistics networks. These converging trends are driving the market towards heightened product differentiation and diversified delivery channels, setting the stage for continued growth and investment opportunities.

Scope & Segmentation

The report comprehensively analyzes the elderly RSV vaccine market across products, end-users, routes of administration, and regional markets to provide a data-driven foundation for strategic planning. The following are the key areas of segmentation and coverage in the research:

  • End Users: Ambulatory Surgical Centers, Clinics, Hospitals
  • Distribution Channels: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
  • Vaccine Types: Live Attenuated, mRNA, Recombinant, Subunit
  • Routes of Administration: Intramuscular, Intranasal
  • Age Cohorts: 65-74 Years, 75-84 Years, 85 Years and Above
  • Regions and Countries: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), and Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Company Coverage: GlaxoSmithKline plc, Pfizer Inc., Moderna, Inc., BioNTech SE, Bavarian Nordic A/S, Novavax, Inc., AstraZeneca plc, Johnson & Johnson, Takeda Pharmaceutical Company Limited, CureVac N.V.

Key Takeaways: Strategic Insights for Senior Decision-Makers

  • Advanced vaccine platforms such as mRNA and recombinant fusion proteins are elevating the immunogenicity and durability of RSV vaccines for elderly cohorts.
  • Strategic industry collaborations—ranging from biopharma partnerships to licensing agreements—are expediting product development, manufacturing scalability, and global distribution.
  • Regional considerations such as public-private partnerships in the Americas, robust national immunization programs in Asia-Pacific, and centralized health technology assessments in Europe impact deployment models and market access.
  • Distribution channels are diversifying, with the rise of online and retail pharmacy services enhancing outreach to target demographics, especially through integration with telehealth and community-based care.
  • Tailored vaccine messaging and delivery strategies are necessary to meet the unique health priorities of distinct elderly age segments and to optimize vaccine coverage rates.
  • Stakeholder engagement and outcome-focused pricing models are increasingly critical in payer discussions and budget planning.

Tariff Impact on RSV Vaccine Supply Chains

Recent United States tariff changes are altering supply chain costs and dynamics for RSV vaccine manufacturers. Increases in import duties on essential inputs such as recombinant proteins, adjuvants, syringes, and packaging materials are reshaping cost structures and procurement strategies. Manufacturers are responding by seeking alternative sourcing, renegotiating supplier contracts, and adapting distribution networks to preserve continuity and compliance. Downstream, these changes influence healthcare providers and payers as reimbursement and warranty models are adjusted to accommodate new cost realities.

Methodology & Data Sources

This report integrates primary interviews with virology and geriatric experts, as well as secondary literature including regulatory filings, clinical trial registries, peer-reviewed publications, policy documents, and industry white papers. All insights have been validated through triangulation and expert peer review to ensure completeness and accuracy.

Why This Report Matters

  • Offers actionable intelligence for investment, procurement, and launch strategies in a shifting elderly RSV vaccine market.
  • Enables benchmarking of platform technologies, regional readiness, and company positioning for executive-level business planning.
  • Supports payer, provider, and policy stakeholder alignment to optimize coverage, reimbursement, and patient outcomes within evolving immunization programs.

Conclusion

Forward-thinking coordination among manufacturers, healthcare systems, and policymakers is essential to advancing RSV vaccination and respiratory health in the aging population. This analysis provides critical guidance to inform next steps in strategy and execution.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Regulatory approval pathways and fast-track designations for RSV vaccines targeting adults over 65
5.2. Integration of mRNA technology advancements into late-stage RSV vaccine candidates for seniors
5.3. Emerging public-private partnerships funding phase III RSV vaccine trials in geriatric populations
5.4. Assessment of healthcare provider education programs to improve RSV vaccination uptake among the elderly
5.5. Pricing and reimbursement strategies influencing adoption of new elderly RSV vaccines across European markets
5.6. Competitive landscape analysis of adjuvant formulations enhancing immune response in older adults
5.7. Impact of real-world evidence studies on safety profiles and long-term efficacy of senior RSV immunizations
5.8. Supply chain optimization initiatives addressing cold-chain logistics for RSV vaccine distribution to nursing homes
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Respiratory Syncytial Virus Vaccine for the Elderly Market, by End User
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Clinics
8.4. Hospitals
9. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Vaccine Type
10.1. Introduction
10.2. Live Attenuated
10.3. mRNA
10.4. Recombinant
10.5. Subunit
11. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Route Of Administration
11.1. Introduction
11.2. Intramuscular
11.3. Intranasal
12. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Age Cohort
12.1. Introduction
12.2. 65-74 Years
12.3. 75-84 Years
12.4. 85 Years And Above
13. Americas Respiratory Syncytial Virus Vaccine for the Elderly Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. GlaxoSmithKline plc
16.3.2. Pfizer Inc.
16.3.3. Moderna, Inc.
16.3.4. BioNTech SE
16.3.5. Bavarian Nordic A/S
16.3.6. Novavax, Inc.
16.3.7. AstraZeneca plc
16.3.8. Johnson & Johnson
16.3.9. Takeda Pharmaceutical Company Limited
16.3.10. CureVac N.V.
17. ResearchAI18. ResearchStatistics19. ResearchContacts20. ResearchArticles21. Appendix
List of Figures
FIGURE 1. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 6. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET: RESEARCHAI
FIGURE 26. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET: RESEARCHSTATISTICS
FIGURE 27. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET: RESEARCHCONTACTS
FIGURE 28. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY SUBUNIT, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY INTRANASAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY 65-74 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY 65-74 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY 75-84 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY 75-84 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY 85 YEARS AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY 85 YEARS AND ABOVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 73. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 78. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 79. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 80. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 81. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)
TABLE 82. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2025-2030 (USD MILLION)
TABLE 83. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 88. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 89. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 90. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 91. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)
TABLE 92. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2025-2030 (USD MILLION)
TABLE 93. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 98. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 99. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 100. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 101. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)
TABLE 102. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2025-2030 (USD MILLION)
TABLE 103. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 108. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 109. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)
TABLE 112. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2025-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2025-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. UNITED KINGDOM RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. UNITED KINGDOM RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 130. UNITED KINGDOM RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 132. UNITED KINGDOM RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)
TABLE 134. UNITED KINGDOM RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2025-2030 (USD MILLION)
TABLE 135. GERMANY RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. GERMANY RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. GERMANY RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. GERMANY RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. GERMANY RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 140. GERMANY RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 141. GERMANY RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 142. GERMANY RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 143. GERMANY RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)
TABLE 144. GERMANY RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2025-2030 (USD MILLION)
TABLE 145. FRANCE RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. FRANCE RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. FRANCE RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. FRANCE RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. FRANCE RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 150. FRANCE RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 151. FRANCE RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 152. FRANCE RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 153. FRANCE RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)
TABLE 154. FRANCE RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2025-2030 (USD MILLION)
TABLE 155. RUSSIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. RUSSIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. RUSSIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. RUSSIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. RUSSIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 160. RUSSIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 161. RUSSIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. RUSSIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. RUSSIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)
TABLE 164. RUSSIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2025-2030 (USD MILLION)
TABLE 165. ITALY RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. ITALY RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. ITALY RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. ITALY RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. ITALY RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 170. ITALY RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 171. ITALY RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. ITALY RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. ITALY RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)
TABLE 174. ITALY RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2025-2030 (USD MILLION)
TABLE 175. SPAIN RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. SPAIN RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. SPAIN RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. SPAIN RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. SPAIN RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 180. SPAIN RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 181. SPAIN RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 182. SPAIN RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 183. SPAIN RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)
TABLE 184. SPAIN RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2025-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2025-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. SAUDI ARABIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. SAUDI ARABIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 200. SAUDI ARABIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. SAUDI ARABIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)
TABLE 204. SAUDI ARABIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2025-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. SOUTH AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. SOUTH AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 210. SOUTH AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. SOUTH AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)
TABLE 214. SOUTH AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2025-2030 (USD MILLION)
TABLE 215. DENMARK RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. DENMARK RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. DENMARK RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. DENMARK RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. DENMARK RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 220. DENMARK RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 221. DENMARK RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. DENMARK RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. DENMARK RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)
TABLE 224. DENMARK RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2025-2030 (USD MILLION)
TABLE 225. NETHERLANDS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. NETHERLANDS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. NETHERLANDS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. NETHERLANDS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. NETHERLANDS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 230. NETHERLANDS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 231. NETHERLANDS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. NETHERLANDS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. NETHERLANDS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)
TABLE 234. NETHERLANDS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2025-2030 (USD MILLION)
TABLE 235. QATAR RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. QATAR RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. QATAR RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. QATAR RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. QATAR RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 240. QATAR RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 241. QATAR RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 242. QATAR RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 243. QATAR RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)
TABLE 244. QATAR RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2025-2030 (USD MILLION)
TABLE 245. FINLAND RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. FINLAND RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. FINLAND RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. FINLAND RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. FINLAND RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 250. FINLAND RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 251. FINLAND RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 252. FINLAND RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 253. FINLAND RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE COHORT, 2018-2024 (USD MILLION)

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Respiratory Syncytial Virus Vaccine for the Elderly market report include:
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Moderna, Inc.
  • BioNTech SE
  • Bavarian Nordic A/S
  • Novavax, Inc.
  • AstraZeneca plc
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • CureVac N.V.

Related Topics

Related Reports

Respiratory Syncytial Virus Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Respiratory Syncytial Virus Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Respiratory Syncytial Virus Vaccine Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Respiratory Syncytial Virus Vaccine Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Respiratory Syncytial Virus Vaccine for Children Market - Global Forecast 2025-2030 - Product Image

Respiratory Syncytial Virus Vaccine for Children Market - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Respiratory Syncytial Virus Vaccines Market Size, Share & Trends Analysis Report By Type (Passive Immunization, Preventive Vaccines), By Technology, By Targeted Population, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Respiratory Syncytial Virus Vaccines Market Size, Share & Trends Analysis Report By Type (Passive Immunization, Preventive Vaccines), By Technology, By Targeted Population, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Human Respiratory Syncytial Virus Treatment Market - Global Forecast 2025-2030 - Product Image

Human Respiratory Syncytial Virus Treatment Market - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.